Pd-1

Phase 3Small molecule

SSichuan Baili Pharmaceutical Co., Ltd.

Pd-1 is one of 423 small molecule programs targeting Glioma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

422

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

Nasopharyngeal CarcinomaActive, not recruiting

Lynch SyndromeActive, not recruiting

Lung CancerActive, not recruiting

Esophageal CancerActive, not recruiting

LymphomaActive, not recruiting

Gastric AdenocarcinomaActive, not recruiting

Liver CancerActive, not recruiting

Colorectal CancerActive, not recruiting

Pancreatic CancerRecruiting

GliomaPhase 2

Active, not recruiting

Nasopharyngeal CarcinomaPhase 2

Active, not recruiting

Lynch SyndromePhase 3

Active, not recruiting

Lung CancerPhase 2

Active, not recruiting

Esophageal CancerPhase 2

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

Gastric AdenocarcinomaPhase 2

Active, not recruiting

Liver CancerPhase 3

Active, not recruiting

Colorectal CancerPhase 2

Active, not recruiting

Pancreatic CancerPhase 2

Recruiting

Showing 10 of 17 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Pd-1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

2 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Zofran

Novartis

Preclinical

2 4

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 5

Tafasitamab

Incyte

Preclinical

7 6

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 8

PEG-Intron

Merck & Co.

Preclinical

1 9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Colorectal Cancer

NCT06301386

Phase 2Recruiting

Lymphoma

NCT04512534

Phase 2Active, not recruiting

Chemoradiotherapy

NCT04833387

Q1 2027

Phase 2Recruiting

Locally-Advanced Rectal Cancer

NCT06840665

Phase 2Recruiting

Chemoradiotherapy

NCT06462053

Q4 2027

Phase 2Recruiting

Pancreatic Cancer

NCT06359275

Clinical

Trials by Indication[1]

PD-1antibody10 trials

PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL

Recruiting·RRuijin Hospital·Phase 2·NCT07380984·47 enrolled

Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence

Unknown status·FFudan University·Phase 1/2·NCT04782804·30 enrolled

Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC

Withdrawn·SSun Yat-sen University·Phase 2·NCT03746249

Show 7 more trials

Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria

Withdrawn·SSun Yat-sen University·Phase 3·NCT03791918

TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC

Withdrawn·SSun Yat-sen University·Phase 2·NCT03782831

Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC

Withdrawn·SSun Yat-sen University·Phase 3·NCT03744247

HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC

Withdrawn·SSun Yat-sen University·Phase 2·NCT03803254

Lenvatinib Plus PD-1 Antibody for Unresectable ICC

Suspended·SShi Ming·Phase 2·NCT03779100·25 enrolled

Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria

Withdrawn·SShi Ming·Phase 2·NCT03775707

HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC

Withdrawn·SSun Yat-sen University·Phase 2·NCT03780634

Locally-advanced Rectal Cancer7 trials

MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer

Recruiting·FFudan University·Phase 2·NCT06840665·46 enrolled

CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer

Recruiting·FFudan University·Phase 2·NCT06281405·192 enrolled

Neoadjuvant Short-course Radiotherapy Followed by the Combination of Immunotherapy and Chemotherapy in Locally Advanced Rectal Cancer

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT04663763·40 enrolled

Show 4 more trials

The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer

Unknown status·FFudan University·Phase 2·NCT04411524·50 enrolled

Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer

Completed·FFudan University·Phase 2·NCT04518280·130 enrolled

The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSS Locally Advanced Rectal Cancer

Unknown status·FFudan University·Phase 2·NCT04411537·50 enrolled

Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer

Recruiting·FFudan University·Phase 2·NCT07154316·138 enrolled

Nasopharyngeal Carcinoma4 trials

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Recruiting·SSun Yat-Sen University Cancer Center·Phase 1/2·NCT06802835·148 enrolled

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

Recruiting·SSun Yat-sen University·Phase 3·NCT05342792·556 enrolled

Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT07110558·59 enrolled

Show 1 more trial

Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Completed·WWei Jiang·Phase 2·NCT04350190·25 enrolled

Colorectal Cancer3 trials

Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients

Not yet recruiting·FFudan University·Phase 2·NCT06999252·20 enrolled

Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients

Not yet recruiting·FFudan University·Phase 2·NCT06301386·25 enrolled

PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT04301557·25 enrolled

Chemoradiotherapy3 trials

Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ

Unknown status·PPeking University·Phase 1/2·NCT04061928·45 enrolled

Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer

Recruiting·FFudan University·Phase 2·NCT06462053·134 enrolled

PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT04833387·30 enrolled

34 more indications

Hepatocellular Carcinoma2 trials

Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma

Unknown status·GGuangxi Medical University··NCT04152356·50 enrolled

Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy

Unknown status·—·Phase 2·NCT05962450·84 enrolled

Immunotherapy2 trials

The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer

Recruiting·FFudan University·Phase 2·NCT05555888·34 enrolled

A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection

Unknown status·—·N/A·NCT03914352·40 enrolled

Rectal Cancer2 trials

Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer

Recruiting·SSir Run Run Shaw Hospital·Phase 2·NCT05972655·32 enrolled

Node-sparing Modified Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Locally Advanced of Middle and Low Rectal Cancer : An Randomized, Prospective, Multicenter, Open-label, Phase III Clinical Trial (mRCAT-III)

Active, not recruiting·SSir Run Run Shaw Hospital·Phase 3·NCT06507371·170 enrolled

Lymphoma2 trials

Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma

Recruiting·FFudan University·Phase 2·NCT04512534·51 enrolled

Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma

Terminated·AAdagene (Suzhou) Limited·Phase 1/2·NCT04775680·25 enrolled

Cervical Cancer2 trials

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

Recruiting·NN.N. Alexandrov National Cancer Centre·Phase 2/3·NCT07472153·120 enrolled

Pd-1 Antibody Combined CCRT for Local Advanced Cervical Cancer.

Unknown status·PPeking University Third Hospital·Phase 1/2·NCT04368273·30 enrolled

PD-1 Inhibitor2 trials

Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)

Recruiting·FFudan University·Phase 2·NCT06455124·60 enrolled

Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC

Unknown status·JJiangxi Provincial Cancer Hospital·Phase 3·NCT04557020·200 enrolled

Hypofractionated Radiotherapy2 trials

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

Recruiting·FFudan University·Phase 2·NCT06928584·221 enrolled

The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer

Recruiting·FFudan University·Phase 2·NCT05628038·93 enrolled

First-line Treatment1 trial

The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT05640726·30 enrolled

Neoadjuvant Therapy1 trial

NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC

Not yet recruiting·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 1·NCT07318636·10 enrolled

Targeted Therapy1 trial

Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM

Not yet recruiting·JJun Huang·Phase 2·NCT07381309·114 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma

Unknown status·SSinocelltech Ltd.·Phase 2·NCT04146181·103 enrolled

Liver Metastases1 trial

Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence

Unknown status·FFudan University·Phase 2·NCT06120127·80 enrolled

Advanced Solid Tumors1 trial

Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors

Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT04569916·30 enrolled

Elderly Patients1 trial

Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL

Unknown status·HHuiqiang Huang·Phase 1/2·NCT04796857·30 enrolled

First-line1 trial

CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC

Not yet recruiting·FFudan University·Phase 2·NCT06665087·110 enrolled

Adjuvant Therapy1 trial

PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery

Unknown status·FFudan University·Phase 2·NCT05468138·141 enrolled

Lynch syndrome1 trial

PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients

Unknown status·SSun Yat-sen University·Phase 3·NCT04711434·260 enrolled

Esophageal Cancer1 trial

Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer

Completed·—·Phase 2·NCT04821765·35 enrolled

Gastric Cancer1 trial

PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.

Completed·SSun Yat-sen University·Phase 2·NCT03755440·6 enrolled

Lung Cancer1 trial

Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer

Terminated·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT04422392·93 enrolled

Recurrent Rectal Cancer1 trial

Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer

Not yet recruiting·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 2·NCT06751394·44 enrolled

Gastric Adenocarcinoma1 trial

PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma

Unknown status·—·Phase 2·NCT04006821·30 enrolled

Advanced Solid Tumor1 trial

Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody

Unknown status·HHenan Cancer Hospital·Phase 2/3·NCT03975036·100 enrolled

Randomised Controlled Trial1 trial

PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial

Unknown status·XXuhua Duan·Phase 2/3·NCT05605613·150 enrolled

Patients With Advanced Solid Tumors1 trial

A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors

Recruiting·SSuzhou Genhouse Bio Co., Ltd.·Phase 2·NCT06322095·72 enrolled

Urothelial Carcinoma1 trial

A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 2·NCT06405425·52 enrolled

Glioma1 trial

Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma

Unknown status·SSun Yat-sen University·Phase 2·NCT04588987·60 enrolled

Bladder Cancer1 trial

Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer

Unknown status·TTianjin Medical University Second Hospital·Phase 2·NCT04101812·60 enrolled

Liver Cancer1 trial

Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer

Unknown status·GGuangxi Medical University·Phase 3·NCT04163237·50 enrolled

Total Neoadjuvant Therapy1 trial

Total Neoadjuvant Therapy With PD-1 for Locally Advcancer Rectal Cancer

Not yet recruiting·TThe First Affiliated Hospital of University of Science and Technology of China·Phase 2·NCT07214142·30 enrolled

Patients With Solid Tumors1 trial

Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors

Unknown status·SSir Run Run Shaw Hospital·Phase 1·NCT04864379·30 enrolled

Esophageal Squamous Carcinoma1 trial

A Prospective, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitor Plus Platinum-Based Chemotherapy

Not yet recruiting·BBeijing GoBroad Hospital·Phase 2·NCT07688291·40 enrolled

Esophageal Squamous Cell Carcinoma1 trial

An Open-Label, Randomized Phase II Study of Becotatug Vedotin With or Without PD-1 Inhibitor Immunotherapy in Patients With Advanced Esophageal Squamous Cell Carcinoma Refractory to Previous Immunochemotherapy

Recruiting·FFudan University·Phase 2·NCT07403136·104 enrolled

Pancreatic Cancer1 trial

A Phase II Study on the Safety and Efficacy of PD-1 Combined With Nab-paclitaxel/Gemcitabine and PULSAR in the Treatment of Locally Advanced Unresectable Pancreatic Cancer and Local Recurrence After Surgery.

Recruiting·FFudan University·Phase 2·NCT06359275·81 enrolled

Sources

References

[1]
ClinicalTrials.gov — 68 trial records for Pd-1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pd-1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pd-1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sichuan Baili Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSichuan Baili Pharmaceutical Co., Ltd.

Pd-1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q4 2027

Trials by Indication[1]

PD-1antibody10 trials

Locally-advanced Rectal Cancer7 trials

Nasopharyngeal Carcinoma4 trials

Colorectal Cancer3 trials

Chemoradiotherapy3 trials

Hepatocellular Carcinoma2 trials

Immunotherapy2 trials

Rectal Cancer2 trials

Lymphoma2 trials

Cervical Cancer2 trials

PD-1 Inhibitor2 trials

Hypofractionated Radiotherapy2 trials

First-line Treatment1 trial

Neoadjuvant Therapy1 trial

Targeted Therapy1 trial

Head and Neck Squamous Cell Carcinoma1 trial

Liver Metastases1 trial

Advanced Solid Tumors1 trial

Elderly Patients1 trial

First-line1 trial

Adjuvant Therapy1 trial

Lynch syndrome1 trial

Esophageal Cancer1 trial

Gastric Cancer1 trial

Lung Cancer1 trial

Recurrent Rectal Cancer1 trial

Gastric Adenocarcinoma1 trial

Advanced Solid Tumor1 trial

Randomised Controlled Trial1 trial

Patients With Advanced Solid Tumors1 trial

Urothelial Carcinoma1 trial

Glioma1 trial

Bladder Cancer1 trial

Liver Cancer1 trial

Total Neoadjuvant Therapy1 trial

Patients With Solid Tumors1 trial

Esophageal Squamous Carcinoma1 trial

Esophageal Squamous Cell Carcinoma1 trial

Pancreatic Cancer1 trial

References

Drug Info

Quick Facts

Related News